News
There are currently no news stories available for this symbol.
RELATED RESOURCES |
Snapshot: KUREKRANESHARES MSCI ALL CHINA HEALTH CARE INDEX ETF19.44 as of 4:10:00pm ET 06/05/2023
Quotes delayed at least 15 min.
Log in for real time quote.
|
ETP TypeETF Net Assets
|
30-day SEC Yield AS OF 04/03/2023 | 0.00% |
---|---|
Distribution Yield (TTM) AS OF 04/28/2023 |
0.05% |
KURE KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX ETF |
Asset Class Median | |
---|---|---|
Volume (10-Day Avg) AS OF 06/02/2023 |
35.5K | 13.1M |
1 Month Market Total Return AS OF 06/03/2023 |
-5.12 | +0.22% |
1 Year Market Total Return AS OF 04/30/2023 |
+2.74 | +2.06% |
3 Year Annualized Market Total Return AS OF 04/30/2023 |
-2.57 | +10.76% |
Beta (1 Year Month-End) AS OF 06/03/2023 |
0.65% | 1.00 |
Annual Turnover Ratio AS OF 03/31/2022 |
44.00% | 26.00% |
Net Expense Ratio AS OF 08/01/2022 |
0.65% | 0.50% |
NAV Return | Market Return | |
---|---|---|
1 Year | -12.65 | -11.85 |
3 Year | +0.02 | -0.36 |
5 Year | -2.11 | -2.77 |
10 Year | -- | -- |
Life | -0.82 | -0.83 |
The performance data featured represents past performance, which is no guarantee of future results. Investment return and principal value of an investment will fluctuate; therefore, you may have a gain or loss when you sell your shares. Current performance may be higher or lower than the performance data quoted.
More about Performance & Risk2269 | WuXi Biologics (Cayman) Inc | 8.19% |
---|---|---|
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 6.50% | |
Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 5.29% | |
6160 | BeiGene Ltd Ordinary Shares | 4.79% |
1093 | CSPC Pharmaceutical Group Ltd | 3.66% |
Aier Eye Hospital Group Co Ltd Class A | 3.63% | |
Wuxi AppTec Co Ltd Class A | 2.98% | |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Class A | 2.80% | |
1177 | Sino Biopharmaceutical Ltd | 2.27% |
Chongqing Zhifei Biological Products Co Ltd Class A | 2.24% |
Commentary
For China Healthcare Advancements, Call on KURE
ETF Database - 03/28/2023China is home to one of the largest healthcare markets and, from an investment prospective, one of the most compelling in the emerging world. Among the reasons for that are a burgeoning biotechnology industry, an aging population, and increasing digitization, among...
More